Valeant and Salix Agree on Amended Terms to Merger Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Jefferies Downgrades Salix Pharmaceuticals (SLXP) to Hold; VRX Raised Bid Appears Final
March 18, 2015 7:13 AM EDTJefferies downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Hold with a price target of $173.00 (from $149.00), saying the $173/share raised offer from Valeant Pharma (NYSE: VRX) appears final.
Analyst David Steinberg commented,... More
